Akebia Therapeutics: Renal Insufficiency trials
The registry lists 14 Renal Insufficiency studies with Akebia Therapeutics as lead sponsor. 0 are open to participants now and 11 have results posted.
Phase 1 3Phase 2 5Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02892149Phase 3Results posted
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02865850Phase 3Results posted
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT02680574Phase 3Results posted
- Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney DiseaseCompletedNCT02648347Phase 3Results posted
- 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisCompletedNCT02260193Phase 2Results posted
- 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01906489Phase 2Results posted
- A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on DialysisCompletedNCT01554982Phase 3Results posted
- 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01381094Phase 2Results posted
- Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01235936Phase 2Results posted
- A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on DialysisCompletedNCT01191255Phase 3Results posted
- A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)CompletedNCT00648167Phase 2Results posted
- Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult SubjectsCompletedNCT02412449Phase 1
- Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548CompletedNCT02327546Phase 1
- Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy VolunteersCompletedNCT02062203Phase 1